Pfizer (PFE) closed Friday at $25.33, down 1.63%, underperforming the broader market as the S&P 500 slipped 1.24% but still managed to secure a seventh consecutive weekly gain. The pharmaceutical giant's stock has now fallen roughly 1.4% from its May 8 close of $25.68, reflecting persistent investor caution despite a solid first-quarter earnings beat.
Earnings and Guidance
Pfizer reported first-quarter revenue of $14.451 billion, a 5% year-over-year increase, with adjusted diluted earnings per share of 75 cents, excluding certain charges. The company reaffirmed its full-year 2026 outlook, projecting revenue between $59.5 billion and $62.5 billion and adjusted EPS in the range of $2.80 to $3.00. However, shares have failed to rally on the numbers, suggesting that investors are looking beyond near-term results.
Pipeline and Competitive Pressures
CEO Albert Bourla emphasized that Pfizer is "off to a strong start" for 2026, highlighting oncology and obesity as key areas where the company is "positioned to lead." CFO David Denton noted that operational revenue growth, excluding currency effects, reached 22% for products already on the market or recently acquired. Despite these assurances, analysts remain cautious. Trung Huynh at RBC Capital described Pfizer as "a catalyst story, not an earnings story," while Chris Schott at J.P. Morgan said investors need to see additional clinical data and reduced pipeline risk before sentiment shifts.
The competitive landscape is dominated by Eli Lilly, whose GLP-1 drugs for diabetes and obesity have set a high bar. Pfizer, after acquiring Metsera for $10 billion, does not expect to launch its first obesity drug before 2028, and only if clinical trials succeed. Chief U.S. Commercial Officer Aamir Malik said Pfizer brings "unique capabilities" to the obesity space, but the timeline remains a source of uncertainty.
Product Performance and Dividends
Established drugs continue to provide support. Eliquis, co-marketed with Bristol Myers Squibb, generated $2.17 billion in first-quarter sales. Newer products like Padcev and Nurtec helped offset the decline from COVID-19 treatments, while revenue from the Comirnaty vaccine fell 59% year over year. Pfizer paid $2.4 billion in dividends to shareholders in the first quarter, or 43 cents per share, but has not repurchased any shares in 2026, and its guidance excludes buybacks.
Market Context
The broader market faces headwinds as Treasury yields rise, drawing investor interest toward bonds and pressuring equity valuations. With the S&P 500 near all-time highs, major company-specific news can be overshadowed by macroeconomic shifts. Nvidia is set to report on Wednesday, and Walmart follows on Thursday, which could further divert attention from Pfizer.
Outlook
Pfizer enters a new week under scrutiny. The company's first-quarter beat and reaffirmed guidance provide a foundation, but pipeline uncertainties and competitive dynamics weigh on sentiment. If yields continue to climb or pipeline updates disappoint, Friday's decline may prove to be more than a macro-driven move. Conversely, positive clinical data or a shift in market conditions could help restore confidence. For now, investors are watching closely to see if Pfizer can break free from its recent slump.
